Latest news
{{'2021-06-04T18:10:34Z' | dateFormatFilter}}
Wegovy™ (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US
Read more
{{'2021-06-01T05:30:36Z' | dateFormatFilter}}
Heartseed and Novo Nordisk enter into global collaboration and licence agreement for stem cell-based therapy for heart failure
Read more
{{'2021-05-28T14:17:04Z' | dateFormatFilter}}
Novo Nordisk resubmits once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes for US regulatory approval
Read more
Career Opportunities
Here are our current job openings. If there is not a job you are looking for, you are welcome to create a job agent or a candidate profile.
Investors
Share price
{{priceData.date}} {{priceData.time}}
